ALNYLAM PHARMACEUTICALS, INC. Total Revenue

Quick Answer

ALNYLAM PHARMACEUTICALS, INC. reported Total Revenue of $3.71 billion for the year ending 2025.

  • ALNYLAM PHARMACEUTICALS, INC. showed an increase of +65.2% in Total Revenue from 2024 to 2025.
  • This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2017: $18.96 million | Q2 2017: $15.93 million | Q3 2017: $17.10 million | Q4 2017: $37.92 million | Q1 2018: $21.90 million | Q2 2018: $29.91 million | Q3 2018: $2.07 million | Q4 2018: $21.03 million | Q1 2019: $33.29 million | Q2 2019: $44.71 million | Q3 2019: $70.06 million | Q4 2019: $71.68 million | Q1 2020: $99.48 million | Q2 2020: $103.96 million | Q3 2020: $125.85 million | Q3 2020: $125.85 million | Q4 2020: $163.56 million | Q1 2021: $177.57 million | Q1 2021: $177.57 million | Q2 2021: $220.55 million | Q2 2021: $220.55 million | Q3 2021: $187.63 million | Q1 2022: $213.26 million | Q1 2022: $213.26 million | Q2 2022: $224.82 million | Q2 2022: $224.82 million | Q3 2022: $264.31 million | Q3 2022: $264.31 million | Q1 2023: $319.29 million | Q2 2023: $318.75 million | Q3 2023: $750.53 million | Q1 2024: $494.33 million | Q2 2024: $659.83 million | Q3 2024: $500.92 million | Q1 2025: $594.19 million | Q2 2025: $773.69 million | Q3 2025: $1.25 billion.
  • Over the full 15 years of available data (2016 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Total Revenue has grown by 7,775.4%.
  • Historical annual values: Fiscal year 2025: $3.71 billion | Fiscal year 2024: $2.25 billion | Fiscal year 2023: $1.83 billion | Fiscal year 2022: $1.04 billion | Fiscal year 2022: $1.04 billion | Fiscal year 2021: $844.29 million | Fiscal year 2021: $844.29 million | Fiscal year 2020: $492.85 million | Fiscal year 2020: $492.85 million | Fiscal year 2019: $219.75 million | Fiscal year 2019: $219.75 million | Fiscal year 2018: $74.91 million | Fiscal year 2017: $2.90 million | Fiscal year 2017: $89.91 million | Fiscal year 2016: $47.16 million.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: